{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:17:45Z","timestamp":1762175865830},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1038\/ncpgasthep0338","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T11:19:50Z","timestamp":1133781590000},"page":"572-579","source":"Crossref","is-referenced-by-count":12,"title":["Managing complicated Crohn's disease in children and adolescents"],"prefix":"10.1038","volume":"2","author":[{"given":"Matjaz","family":"Homan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N","family":"Baldassano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petar","family":"Mamula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpgasthep0338_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/adc.85.5.435","volume":"85","author":"HR Jenkins","year":"2001","unstructured":"Jenkins HR (2001) Inflammatory bowel disease. Arch Dis Child 85: 435\u2013437","journal-title":"Arch Dis Child"},{"key":"BFncpgasthep0338_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1067\/S0022-3476(03)00444-X","volume":"143","author":"S Kugathasan","year":"2003","unstructured":"Kugathasan S et al. (2003) Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 143: 525\u2013531","journal-title":"J Pediatr"},{"key":"BFncpgasthep0338_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0889-8553(03)00046-3","volume":"32","author":"P Mamula","year":"2003","unstructured":"Mamula P et al. (2003) Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 32: 967\u2013995","journal-title":"Gastroenterol Clin North Am"},{"key":"BFncpgasthep0338_CR4","first-page":"423","volume":"75","author":"JR Barton","year":"1990","unstructured":"Barton JR and Ferguson A (1990) Clinical features, morbidity and mortality of Scottish children with inflammatory bowel disease. Q J Med 75: 423\u2013439","journal-title":"Q J Med"},{"key":"BFncpgasthep0338_CR5","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/j.1572-0241.2002.05915.x","volume":"97","author":"P Mamula","year":"2002","unstructured":"Mamula P et al. (2002) Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 97: 2005\u20132010","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR6","first-page":"928","volume":"97","author":"J Markowitz","year":"2002","unstructured":"Markowitz J et al. (2002) Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990\u20132000. Am J Gastroenterol 97: 928\u2013932","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1046\/j.1365-2036.2002.01269.x","volume":"16","author":"A Barabino","year":"2002","unstructured":"Barabino A et al. (2002) Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther 16: 1125\u20131130","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0338_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/00005176-199105000-00004","volume":"12","author":"E Seidman","year":"1991","unstructured":"Seidman E et al. (1991) Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 12: 424\u2013438","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0016-5085(88)80072-6","volume":"95","author":"M Kanof","year":"1988","unstructured":"Kanof M et al. (1988) Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 95: 1523\u20131527","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","volume":"12","author":"JS Hyams","year":"1991","unstructured":"Hyams JS et al. (1991) Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12: 439\u2013447","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR11","first-page":"253","volume":"12","author":"M Stephens","year":"2001","unstructured":"Stephens M et al. (2001) Growth failure in the child with inflammatory bowel disease. Semin Gastrointest Dis 12: 253\u2013262","journal-title":"Semin Gastrointest Dis"},{"key":"BFncpgasthep0338_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00005176-200007000-00009","volume":"31","author":"T Sentongo","year":"2000","unstructured":"Sentongo T et al. (2000) Growth, body composition, and nutritional status in children and adolescents with Crohn's disease. J Pediatr Gastroenterol Nutr 31: 33\u201340","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR13","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/BF02532536","volume":"155","author":"J Henker","year":"1996","unstructured":"Henker J (1996) Therapy with recombinant growth hormone in children with Crohn disease and growth failure. Eur J Pediatr 155: 1066\u20131067","journal-title":"Eur J Pediatr"},{"key":"BFncpgasthep0338_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/01.MIB.0000159321.58773.a6","volume":"11","author":"KA Calenda","year":"2005","unstructured":"Calenda KA et al. (2005) Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis 11: 435\u2013441","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0338_CR15","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.dld.2003.12.014","volume":"36","author":"O Borrelli","year":"2004","unstructured":"Borrelli O et al. (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 36: 342\u2013347","journal-title":"Dig Liver Dis"},{"key":"BFncpgasthep0338_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0950-3528(06)80020-5","volume":"8","author":"CE Brain","year":"1994","unstructured":"Brain CE and Savage MO (1994) Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 8: 83\u2013100","journal-title":"Baillieres Clin Gastroenterol"},{"key":"BFncpgasthep0338_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00005176-200203000-00001","volume":"34","author":"R Baldassano","year":"2002","unstructured":"Baldassano R et al. (2002) Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 34: 245\u2013248","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR18","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0016-5085(97)70055-6","volume":"112","author":"E Semeao","year":"1997","unstructured":"Semeao E et al. (1997) Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 112: 1710\u20131713","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0022-3476(99)70058-2","volume":"135","author":"EJ Semeao","year":"1999","unstructured":"Semeao EJ et al. (1999) Risk factors for low bone mineral density in children and young adults with Crohn's disease. J Pediatr 135: 593\u2013600","journal-title":"J Pediatr"},{"key":"BFncpgasthep0338_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/adc.75.4.351","volume":"75","author":"JA Walker-Smith","year":"1996","unstructured":"Walker-Smith JA (1996) Management of growth failure in Crohn's disease. Arch Dis Child 75: 351\u2013354","journal-title":"Arch Dis Child"},{"key":"BFncpgasthep0338_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"WA Faubion Jr","year":"2001","unstructured":"Faubion WA Jr et al. (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121: 255\u2013260","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00042737-200401000-00008","volume":"16","author":"JC Escher","year":"2004","unstructured":"Escher JC (2004) Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 16: 47\u201354","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0338_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","volume":"3","author":"EJ Schoon","year":"2005","unstructured":"Schoon EJ et al. (2005) Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 3: 113\u2013121","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFncpgasthep0338_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","volume":"97","author":"M Cino","year":"2002","unstructured":"Cino M and Greenberg GR (2002) Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 97: 915\u2013921","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00005176-200107000-00013","volume":"33","author":"P Kundhal","year":"2001","unstructured":"Kundhal P et al. (2001) Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 33: 75\u201380","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR26","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/0016-5085(95)90203-1","volume":"108","author":"A Griffiths","year":"1995","unstructured":"Griffiths A et al. (1995) Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 108: 1056\u20131067","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005176-200007000-00005","volume":"31","author":"RB Heuschkel","year":"2000","unstructured":"Heuschkel RB et al. (2000) Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 31: 8\u201315","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1651-2227.2004.tb02956.x","volume":"93","author":"JF Ludvigsson","year":"2004","unstructured":"Ludvigsson JF et al. (2004) Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr 93: 327\u2013335","journal-title":"Acta Paediatr"},{"key":"BFncpgasthep0338_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","volume":"123","author":"DC Pearson","year":"1995","unstructured":"Pearson DC et al. (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123: 132\u2013142","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep0338_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1053\/gast.2000.18144","volume":"119","author":"J Markowitz","year":"2000","unstructured":"Markowitz J et al. (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119: 895\u2013902","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","volume":"11","author":"DA Jacobstein","year":"2005","unstructured":"Jacobstein DA et al. (2005) Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 11: 442\u2013446","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0338_CR32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0016-5085(98)70251-3","volume":"115","author":"B Kirschner","year":"1998","unstructured":"Kirschner B (1998) Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115: 813\u2013821","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","volume":"118","author":"MC Dubinsky","year":"2000","unstructured":"Dubinsky MC et al. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705\u2013713","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00004836-200209000-00008","volume":"35","author":"M Regueiro","year":"2002","unstructured":"Regueiro M and Mardini H (2002) Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 35: 240\u2013244","journal-title":"J Clin Gastroenterol"},{"key":"BFncpgasthep0338_CR35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/gut.2003.032896","volume":"53","author":"S Wright","year":"2004","unstructured":"Wright S et al. (2004) Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53: 1123\u20131128","journal-title":"Gut"},{"key":"BFncpgasthep0338_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00042737-200303000-00003","volume":"15","author":"AG Fraser","year":"2003","unstructured":"Fraser AG (2003) Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol 15: 225\u2013231","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0338_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199502023320503","volume":"332","author":"BG Feagan","year":"1995","unstructured":"Feagan BG et al. (1995) Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332: 292\u2013297","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0338_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0022-3476(98)70313-0","volume":"132","author":"DR Mack","year":"1998","unstructured":"Mack DR et al. (1998) Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 132: 830\u2013835","journal-title":"J Pediatr"},{"key":"BFncpgasthep0338_CR39","doi-asserted-by":"publisher","first-page":"A392","DOI":"10.1097\/00005176-200309000-00043","volume":"37","author":"JR Rosh","year":"2003","unstructured":"Rosh JR et al. (2003) Efficacy of methotrexate as a maintenance agent in pediatric Crohn's disease [abstract]. J Pediatr Gastroenterol Nutr 37: A392","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/01.MPG.0000157588.27125.50","volume":"40","author":"MC Stephens","year":"2005","unstructured":"Stephens MC et al. (2005) The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 40: 445\u2013449","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1365-2036.2003.01614.x","volume":"18","author":"D Kurnik","year":"2003","unstructured":"Kurnik D et al. (2003) Bioavailability of oral versus subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 18: 57\u201363","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0338_CR42","first-page":"1355","volume":"91","author":"G Mahdi","year":"1996","unstructured":"Mahdi G et al. (1996) Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am J Gastroenterol 91: 1355\u20131359","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00005176-199604000-00012","volume":"22","author":"J Ramakrishna","year":"1996","unstructured":"Ramakrishna J et al. (1996) Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 22: 296\u2013302","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR44","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1345\/aph.1C039","volume":"37","author":"IK Nahar","year":"2003","unstructured":"Nahar IK et al. (2003) Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 37: 1256\u20131265","journal-title":"Ann Pharmacother"},{"key":"BFncpgasthep0338_CR45","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00054725-200411000-00008","volume":"10","author":"T Lamireau","year":"2004","unstructured":"Lamireau T et al. (2004) Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 10: 745\u2013750","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0338_CR46","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","volume":"98","author":"R Baldassano","year":"2003","unstructured":"Baldassano R et al. (2003) Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 98: 833\u2013838","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/00005176-200407000-00010","volume":"39","author":"L de Ridder","year":"2004","unstructured":"de Ridder L et al. (2004) Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 39: 46\u201352","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00054725-200301000-00006","volume":"9","author":"JC Escher","year":"2003","unstructured":"Escher JC et al. (2003) Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9: 34\u201358","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0338_CR49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/00054725-200407000-00013","volume":"10","author":"K Kooros","year":"2004","unstructured":"Kooros K and Katz AJ (2004) Infliximab therapy in pediatric Crohn's pouchitis. Inflamm Bowel Dis 10: 417\u2013420","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0338_CR50","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/00005176-200305000-00007","volume":"36","author":"JP Cezard","year":"2003","unstructured":"Cezard JP et al. (2003) A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 36: 632\u2013636","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR51","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541\u20131549","journal-title":"Lancet"},{"key":"BFncpgasthep0338_CR52","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00005176-200405000-00008","volume":"38","author":"E Miele","year":"2004","unstructured":"Miele E et al. (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38: 502\u2013508","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR53","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1111\/j.1572-0241.2000.03263.x","volume":"95","author":"S Kugathasan","year":"2000","unstructured":"Kugathasan S et al. (2000) Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 95: 3189\u20133194","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR54","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","volume":"18","author":"P Lionetti","year":"2003","unstructured":"Lionetti P et al. (2003) Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 18: 425\u2013431","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0338_CR55","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876\u2013885","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0338_CR56","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F and Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740\u20131751","journal-title":"Arthritis Rheum"},{"issue":"Suppl C","key":"BFncpgasthep0338_CR57","doi-asserted-by":"publisher","first-page":"29C","DOI":"10.1155\/2000\/698523","volume":"14","author":"TF Schaible","year":"2000","unstructured":"Schaible TF (2000) Long term safety of infliximab. Can J Gastroenterol 14 (Suppl C): 29C\u201332C","journal-title":"Can J Gastroenterol"},{"key":"BFncpgasthep0338_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF et al. (2004) The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19\u201331","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR59","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent. N Engl J Med 345: 1098\u20131104","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0338_CR60","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/art.10583","volume":"46","author":"JH Lee","year":"2002","unstructured":"Lee JH et al. (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor \u03b1 antagonists infliximab and etanercept. Arthritis Rheum 46: 2565\u20132570","journal-title":"Arthritis Rheum"},{"key":"BFncpgasthep0338_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/art.10758","volume":"48","author":"NR Slifman","year":"2003","unstructured":"Slifman NR et al. (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor \u03b1-neutralizing agents. Arthritis Rheum 48: 319\u2013324","journal-title":"Arthritis Rheum"},{"key":"BFncpgasthep0338_CR62","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1111\/j.1572-0241.2000.03363.x","volume":"95","author":"RD Cohen","year":"2000","unstructured":"Cohen RD et al. (2000) Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 95: 3469\u20133477","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/j.1365-2036.2003.01411.x","volume":"17","author":"WV Crandall","year":"2003","unstructured":"Crandall WV and Mackner LM (2003) Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 17: 75\u201384","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0338_CR64","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","volume":"11","author":"DA Jacobstein","year":"2005","unstructured":"Jacobstein DA et al. (2005) Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 11: 442\u2013446","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0338_CR65","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","volume":"97","author":"S Kugathasan","year":"2002","unstructured":"Kugathasan S et al. (2002) Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 97: 1408\u20131414","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR66","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00005176-200405000-00008","volume":"38","author":"E Miele","year":"2004","unstructured":"Miele E et al. (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38: 502\u2013508","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR67","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","volume":"98","author":"M Stephens","year":"2003","unstructured":"Stephens M et al. (2003) Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 98: 104\u2013111","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0338_CR68","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/gut.2003.035253","volume":"53","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ et al. (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor \u03b1, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53: 1485\u20131493","journal-title":"Gut"},{"key":"BFncpgasthep0338_CR69","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/00054725-200411000-00005","volume":"10","author":"P Mamula","year":"2004","unstructured":"Mamula P et al. (2004) CDP571, a humanized anti-tumor necrosis factor-\u03b1 monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 10: 723\u2013730","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0338_CR70","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/01.mpg.0000169275.86308.b0","volume":"41","author":"S Mian","year":"2005","unstructured":"Mian S and Baron H (2005) Adalimumab, a novel anti-tumor necrosis factor-\u03b1 antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 41: 357\u2013359","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","volume":"100","author":"KA Papadakis","year":"2005","unstructured":"Papadakis KA et al. (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100: 75\u201379","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"BFncpgasthep0338_CR72","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00005176-200406001-00109","volume":"39","author":"J Hyams","year":"2004","unstructured":"Hyams J et al. (2004) A phase II, multicenter, open-label study of the safety, tolerability, and effectiveness of natalizumab in adolescents with moderately to severely active Crohn's disease. J Pediatr Gastroenterol Nutr 39 (Suppl 1): S49","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFncpgasthep0338_CR73","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362\u2013368","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0338_CR74","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1053\/j.gastro.2004.11.051","volume":"128","author":"Y Oyama","year":"2005","unstructured":"Oyama Y et al. (2005) Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128: 552\u2013563","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0338_CR75","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa041109","volume":"352","author":"JR Korzenik","year":"2005","unstructured":"Korzenik JR et al. (2005) Sargramostim for active Crohn's disease. N Engl J Med 352: 2193\u20132201","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0338_CR76","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00054725-200011000-00001","volume":"6","author":"TA Sentongo","year":"2000","unstructured":"Sentongo TA et al. (2000) Growth after intestinal resection for Crohn's disease in children, adolescents, and young adults. Inflamm Bowel Dis 6: 265\u2013269","journal-title":"Inflamm Bowel Dis"}],"container-title":["Nature Clinical Practice Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0338","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T05:03:59Z","timestamp":1649912639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":76,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12,1]]}},"alternative-id":["BFncpgasthep0338"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep0338","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}